HANGZHOU, China and SHANGHAI and BOSTON, July 14, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9...
Hence then, the article about lynk pharmaceuticals announces completion of patient enrollment in phase iii clinical trial of zemprocitinib for ankylosing spondylitis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis )
Also on site :
- How US commerce secretary's Epstein links were uncovered by British whistleblower
- Starbucks Debuts Four Unexpected New Drinks That Fans are Already 'Obsessed' With: 'Can't Wait to Try'
- Amid the Gulf’s increasingly competitive investment landscape, Bahrain is carving out a distinct investment strategy